Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALLO NASDAQ:BTAI NASDAQ:BYND On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALLOAllogene Therapeutics$1.29+4.5%$1.17$0.86▼$3.78$285.12M0.434.16 million shs1.23 million shsBTAIBioXcel Therapeutics$2.66+1.3%$3.69$1.17▼$13.28$42.51M0.184.72 million shs624,003 shsBYNDBeyond Meat$0.81+3.2%$2.47$0.75▼$6.70$61.86M2.334.73 million shs44.63 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for October 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALLOAllogene Therapeutics-3.15%-8.89%+8.85%0.00%-53.23%BTAIBioXcel Therapeutics+0.38%+4.80%-15.76%+34.36%-69.47%BYNDBeyond Meat-24.19%-64.18%-70.87%-76.62%-88.22%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALLOAllogene Therapeutics$1.29+4.5%$1.17$0.86▼$3.78$285.12M0.434.16 million shs1.23 million shsBTAIBioXcel Therapeutics$2.66+1.3%$3.69$1.17▼$13.28$42.51M0.184.72 million shs624,003 shsBYNDBeyond Meat$0.81+3.2%$2.47$0.75▼$6.70$61.86M2.334.73 million shs44.63 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for October 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALLOAllogene Therapeutics-3.15%-8.89%+8.85%0.00%-53.23%BTAIBioXcel Therapeutics+0.38%+4.80%-15.76%+34.36%-69.47%BYNDBeyond Meat-24.19%-64.18%-70.87%-76.62%-88.22%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALLOAllogene Therapeutics 2.54Moderate Buy$8.44557.16% UpsideBTAIBioXcel Therapeutics 2.43Hold$39.751,397.18% UpsideBYNDBeyond Meat 1.25Strong Sell$2.27181.22% UpsideCurrent Analyst Ratings BreakdownLatest BYND, ALLO, and BTAI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/14/2025BYNDBeyond MeatCowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell10/14/2025BYNDBeyond MeatTD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetSell$2.00 ➝ $0.8010/10/2025ALLOAllogene TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral ➝ Underweight10/8/2025ALLOAllogene TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025BTAIBioXcel TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025BYNDBeyond MeatWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/30/2025BYNDBeyond MeatBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral9/27/2025ALLOAllogene TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025BTAIBioXcel TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025BYNDBeyond MeatWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/15/2025BTAIBioXcel TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.00(Data available from 10/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALLOAllogene Therapeutics$20K14,255.79N/AN/A$2.01 per share0.64BTAIBioXcel Therapeutics$2.27M18.73N/AN/A($30.01) per share-0.09BYNDBeyond Meat$326.45M0.19N/AN/A($9.22) per share-0.09Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALLOAllogene Therapeutics-$257.59M-$1.11N/AN/AN/AN/A-55.99%-42.75%11/6/2025 (Estimated)BTAIBioXcel Therapeutics-$59.60M-$12.64N/AN/AN/A-5,869.82%N/A-134.45%11/13/2025 (Estimated)BYNDBeyond Meat-$160.28M-$2.18N/AN/AN/A-52.27%N/A-22.97%11/5/2025 (Estimated)Latest BYND, ALLO, and BTAI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/6/2025Q3 2025ALLOAllogene Therapeutics-$0.23N/AN/AN/AN/AN/A11/5/2025Q3 2025BYNDBeyond Meat-$0.39N/AN/AN/A$68.82 millionN/A8/13/2025Q2 2025ALLOAllogene Therapeutics-$0.28-$0.23+$0.05-$0.23N/AN/A8/12/2025Q2 2025BTAIBioXcel Therapeutics-$2.30-$2.45-$0.15-$2.45$0.21 million$0.12 million8/6/2025Q2 2025BYNDBeyond Meat-$0.37-$0.43-$0.06-$0.43$85.71 million$74.96 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALLOAllogene TherapeuticsN/AN/AN/AN/AN/ABTAIBioXcel TherapeuticsN/AN/AN/AN/AN/ABYNDBeyond MeatN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALLOAllogene TherapeuticsN/A8.928.92BTAIBioXcel TherapeuticsN/A0.760.74BYNDBeyond MeatN/A3.292.07Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALLOAllogene Therapeutics83.63%BTAIBioXcel Therapeutics30.68%BYNDBeyond Meat52.48%Insider OwnershipCompanyInsider OwnershipALLOAllogene Therapeutics13.20%BTAIBioXcel Therapeutics21.20%BYNDBeyond Meat7.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALLOAllogene Therapeutics310221.88 million192.59 millionOptionableBTAIBioXcel Therapeutics9016.01 million12.62 millionOptionableBYNDBeyond Meat88076.75 million71.00 millionOptionableBYND, ALLO, and BTAI HeadlinesRecent News About These CompaniesTD Cowen Maintains Beyond Meat (BYND) Sell RecommendationOctober 15 at 5:15 AM | msn.comWhy Beyond Meat (BYND) Stock Is NosedivingOctober 14 at 7:12 PM | msn.comBeyond Meat: I'm Not Comfortable With The Financial SituationOctober 14 at 7:12 PM | seekingalpha.comBeyond Meat shares drop below $1 on investor concerns...October 14 at 3:48 PM | marketbeat.comBeyond Meat stock tanks to $1 after debt swap deal dilutes company sharesOctober 14 at 11:17 AM | nypost.comNTD Cowen Issues Pessimistic Forecast for Beyond Meat (NASDAQ:BYND) Stock PriceOctober 14 at 9:24 AM | marketbeat.comTaylor Swift on Disney+, Beyond Meat nosedives on debt swapOctober 13 at 6:40 PM | finance.yahoo.comBeyond Meat slumps as shareholders agonize over debt exchange offerOctober 13 at 6:40 PM | msn.comBeyond Meat Debt Deal Rattles InvestorsOctober 13 at 4:16 PM | wsj.comBeyond belief: the sizzle has well and truly gone from Beyond MeatOctober 13 at 2:02 PM | proactiveinvestors.comBeyond belief: the sizzle has well and truly gone from Beyond MeatOctober 13 at 1:54 PM | proactiveinvestors.comBeyond Meat plummets after debt swap massively dilutes shareholdersOctober 13 at 1:39 PM | finance.yahoo.comBeyond Meat stock plunges after early debt exchange settlementOctober 13 at 1:39 PM | za.investing.comBeyond Meat sinks after convertible debt exchange rattles investorsOctober 13 at 1:39 PM | msn.comBeyond Meat Shares Plunge After Early Debt Exchange SettlementOctober 13 at 1:39 PM | msn.comWhy Beyond Meat (BYND) Stock Is Falling TodayOctober 13 at 1:39 PM | finance.yahoo.comBeyond Meat slumps after early settlement of convertible debt exchange offerOctober 13 at 8:37 AM | msn.comBeyond Meat Announces Early Tender Results and Early Settlement for Exchange Offer and Consent Solicitation with Respect to Existing Convertible NotesOctober 13 at 7:00 AM | globenewswire.comBeyond Meat, Inc. $BYND Shares Bought by Vontobel Holding Ltd.October 10, 2025 | marketbeat.comWeiss Ratings Reaffirms Sell (E+) Rating for Beyond Meat (NASDAQ:BYND)October 9, 2025 | marketbeat.comBeyond Meat (BYND) Is Up 41.2% After Announcing Major Debt Swap and Share Issuance PlanOctober 6, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSoundHound Breaks Critical Resistance: How High Can It Get Now?By Thomas Hughes | September 28, 2025The Fed Cut Rates: What Now for the S&P 500 and Equity Markets?By Thomas Hughes | September 18, 2025Why Datavault May Be the Penny AI Stock Investors Have Waited ForBy Nathan Reiff | September 22, 2025Treat Your Portfolio With These 3 Spooky Season StocksBy Nathan Reiff | October 8, 2025Applied Digital’s Shorts Got Squeezed—Now What?By Thomas Hughes | October 13, 2025BYND, ALLO, and BTAI Company DescriptionsAllogene Therapeutics NASDAQ:ALLO$1.28 +0.06 (+4.47%) As of 12:31 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.BioXcel Therapeutics NASDAQ:BTAI$2.66 +0.04 (+1.34%) As of 12:32 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the acute treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally innate immunity activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, a drug candidate to target aggression in dementia. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut.Beyond Meat NASDAQ:BYND$0.80 +0.02 (+2.97%) As of 12:32 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Beyond Meat, Inc., a plant-based meat company, develops, manufactures, markets, and sells plant-based meat products in the United States and internationally. The company sells a range of plant-based meat products across the platforms of beef, pork, and poultry. It sells its products through grocery, mass merchandiser, club stores, and natural retailer channels, as well as various food-away-from-home channels, including restaurants, foodservice outlets, and schools. The company was formerly known as Savage River, Inc. and changed its name to Beyond Meat, Inc. in September 2018. Beyond Meat, Inc. was incorporated in 2008 and is headquartered in El Segundo, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Healthcare Companies Insiders Are Buying NVIDIA Analysts Lift Targets: What It Means for the Stock Price Fastenal Stock Pulls Back in October—Is It Time to Buy FAST? 5 Stocks and ETFs to Weather Volatility as Trade Tensions Rise Why Congress Is Buying Intuitive Surgical Ahead of Earnings D-Wave: Reevaluating the Short Seller’s Case After the Downgrade 3 Dividend Hikes That Signal Renewed Strength in 2025 2 Reasons Absci Could Be the Future of AI Biotech, and 1 Risk Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
